Non-Invasive diagnostics for better rhinology treatments

THE PROBLEM

pexels-photo-4492065.jpeg

Antibiotic resistance is one of the biggest growing threats to global health today. It currently results in 700 000 annual deaths; a figure predicted to increase to 10 million deaths per year in 2050.

Currently, upper respiratory infections are mostly diagnosed by physical examination where overlapping symptoms result in 1 out of 3 prescriptions being unnecessary.

Among those, Sinusitis accounts for a total of 77 million primary care visits across the United States, Europe and Australia.

Diag-Nose Medical is working on an affordable, rapid and non-invasive self-test to determine the right treatment pathway for patients with acute sinusitis and to promote antibiotic stewardship for clinicians.

 

Our flagship product, the “RHINOSENSE” is a point of care test that combines non-invasive nasal sampling, lateral flow immunoassays and host-immune markers to differentiate between viral, bacterial and allergy mediated sinusitis.

OUR SOLUTION

Our Partners

Copyright © 2021 Diag-Nose Pty Ltd. All rights reserved.